Aller au contenu principal
xMedica

NCT05922878ClinicalTrials.gov

Study of ALTO-300 in MDD

A Randomized, Double-Blind, Placebo-Controlled Study of ALTO-300 With an Open-Label Extension in Adults With Major Depressive Disorder

En recrutementAccepte des participants actuellement, selon la fiche du registre.
Contacter cette étude

En bref

The purpose of this study is to determine efficacy differences between ALTO-300 and placebo, used adjunctively to an antidepressant, related to patient characteristics.

Phase 2325 participants recherchés75 sites1 pays

Catégories

Enregistré dans 1 registre

Une même étude peut être enregistrée dans plusieurs registres. Nous l'affichons une seule fois et renvoyons vers chaque fiche que nous détenons.

Les informations de l'essai sont affichées telles que publiées par le registre, dans leur langue d'origine.

Cette étude vous intéresse ?

Se connecter ou créez un compte pour manifester votre intérêt et suivre cette étude.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Not stated: Registered after enrolment began (about 20 days after the recorded start)First posted 2023-06-28; recorded start 2023-06-08
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Present: Participants are randomly assignedAllocation is recorded as randomised
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Present: Uses blinding (masking)A masking level is recorded in the record
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 4 other studies in this databaseCounted from the lead sponsor named in the record (Alto Neuroscience)
  • Not stated: No posted results from this sponsor are in this database yetBased on the sponsor’s studies in this database
  • The record lists 1 condition.
  • Lead sponsor type recorded as: industry.
  • Intervention regulatory context: investigational, within a phased regulatory pathway.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourSTRONG

A strong methodological design for a phase 2 study, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation20/20

    Participants are randomly allocated between arms

  • Blinding20/20

    Quadruple-blind

  • Control arm13/15

    Placebo / sham control arm

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre8/8

    Multi-centre: 45 sites

  • Data monitoring committee0/7

    No data monitoring committee stated

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleMEDIUM

A medium-sized study: 325 participants (target), run at 75 sites.

How this score is built
  • Enrolment24/40

    321 participants (target)

  • Site count19/25

    45 sites

  • Country count0/15

    Single country

  • Planned duration8/10

    Planned over about 42 months

  • Sponsor scale2/10

    Alto Neuroscience has led 5 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Résumé

The purpose of this study is to determine efficacy differences between ALTO-300 and placebo, used adjunctively to an antidepressant, related to patient characteristics.

Affections

  • Major Depressive Disorder

Éligibilité

Éligibilité
SexeTous
Âges18 Years – 70 Years
Volontaires sainsNon

Éligibilité telle qu'elle figure dans le registre

Inclusion Criteria: * Have a diagnosis of moderate to severe major depressive disorder (MDD) * At Visit 1, currently taking a stable dose of 1 or 2 antidepressants (e.g., SSRI, SNRI, bupropion, or gepirone) for at least 6 weeks with no dose modifications in the past 2 weeks by Visit 2 * Willing to comply with all study assessments and procedures * Must not be pregnant or breastfeeding at time of enrollment or throughout study Exclusion Criteria: * Evidence of unstable medical condition * Nightly use of sleep medication * Diagnosed bipolar disorder, psychotic disorder, or dementia * Current moderate or severe substance use disorder * Has a history of hypersensitivity or allergic reaction to ALTO-300 or any of its components/excipients * Concurrent or recent participation in another clinical trial for mental illness involving an investigational product or device

Éligibilité en énoncés simples

Les critères de cette fiche n'ont pas encore été décomposés en énoncés distincts. Le texte du registre ci-dessus est complet et fait foi.

Conception de l'étude

Conception de l'étude
Type d'étudeInterventionnelle
PhasePhase 2
RépartitionRandomisée
Modèle d'interventionPARALLEL
Objectif principalTREATMENT
InsuQUADRUPLE (4)
Recrutement325 participants recherchés

Promoteur et collaborateurs

  • Alto Neuroscience Promoteur

Groupes et interventions

  • ALTO-300EXPERIMENTAL

    Participants will receive ALTO-300 25mg capsule once daily in the evening, from Day 1 to Day 42 in double blind (DB) treatment period. Eligible participants who will enter the open-label (OL) treatment period will receive ALTO-300 capsule once daily in the evening from OL baseline until the end of OL period/early termination visit (Up to 8 weeks).

  • PlaceboPLACEBO_COMPARATOR

    Participants will receive matching placebo capsule once daily in the evening, from Day 1 to Day 42 in double blind (DB) treatment period.

Interventions

  • Médicament ALTO-300

    ALTO-300 capsule QD

  • Médicament Placebo

    Placebo capsule QD

Critères de jugement

  1. Critère de jugement principal

    To assess efficacy of adjunctive ALTO-300 versus placebo on symptoms of MDD in a pre-defined subgroup of participants as measured by the change over time up to week 6 in the Montgomery-Åsberg Depression Rating Scale (MADRS).

    MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 60. Higher scores represent a more severe condition.

    Délai Change over time for up to week 6

  2. Critère de jugement secondaire

    To assess efficacy of adjunctive ALTO-300 versus placebo on symptoms of MDD in all randomized participants as measured by the change over time up to week 6 in the Montgomery-Åsberg Depression Rating Scale (MADRS)

    MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 60. Higher scores represent a more severe condition.

    Délai Change over time for up to week 6

  3. Critère de jugement secondaire

    To assess efficacy of adjunctive ALTO-300 versus placebo for MDD as measured by the change over time up to week 6 in response (>50% improvement from baseline) rates based on the MADRS

    MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 60. Higher scores represent a more severe condition.

    Délai Change over time for up to week 6

  4. Critère de jugement secondaire

    To evaluate the safety of ALTO-300 during both the OL and DB periods of the study as measured by the assessment of the incidence, severity, and relatedness of Adverse Events.

    Incidence, severity, and relatedness of Adverse Events

    Délai Assessed from Day 1 to Week 14

  5. Critère de jugement secondaire

    To evaluate the safety of ALTO-300 during both the OL and DB periods of the study as measured by the assessment of Heart Rate.

    Assessment of Heart Rate

    Délai Assessed from Day 1 to Week 14

  6. Critère de jugement secondaire

    To evaluate the safety of ALTO-300 during both the OL and DB periods of the study as measured by the assessment of Weight.

    Assessment of Weight Change

    Délai Assessed from Day 1 to Week 14

  7. Critère de jugement secondaire

    To evaluate the safety of ALTO-300 during both the OL and DB periods of the study as measured by the assessment of Blood Pressure.

    Assessment of Blood Pressure

    Délai Assessed from Day 1 to Week 14

  8. Critère de jugement secondaire

    To evaluate the safety of ALTO-300 during both the OL and DB periods of the study as measured by the assessment of suicidality with the Concise Health Risk Tracking Self-Report,12 item scale (CHRT-SR12).

    The CHRT is a brief, self-report measure that systematically assesses both suicidal thinking and associated thoughts that may indicate the propensity for suicidal acts. The CHRT-SR12 is a 12 item scale. The patient assigns a score of 0-4 for each item of the scale, allowing for a total score of 0 to 48, with the higher score signifying more severe symptoms.

    Délai Assessed from Day 1 to Week 15

Dates

Dates
Date de début8 juin 2023 (réelle)
Achèvement principal1 décembre 2026 (estimée)
Achèvement1 décembre 2026 (estimée)
Première publication28 juin 2023 (réelle)
Dernière mise à jour26 octobre 2026
Résultats publiésNon précisé dans la fiche du registre
Statut vérifié pour la dernière foisoctobre 2026

Réelle signifie que l'événement a eu lieu. Estimée signifie que le promoteur s'y attend. Les deux ont un sens différent.

Lieux

30 sites sont en recrutement

United States

United States
ÉtablissementVilleÉtat ou régionStatut
Site 114AlbuquerqueNew MexicoEn recrutement
Site 216AllentownPennsylvaniaArrêté prématurément
Site 316AustinTexasEn recrutement
Site 218BellflowerCaliforniaEn recrutement
Site 317BlackfootIdahoRetiré
Site 236BoiseIdahoEn recrutement
Site 119BoiseIdahoActif, sans recrutement
Site 318CarlsbadCaliforniaActif, sans recrutement
Site 310ChicagoIllinoisActif, sans recrutement
Site 202CincinnatiOhioEn recrutement
Site 159ClermontFloridaArrêté prématurément
Site 207ClintonUtahActif, sans recrutement
Site 203Colorado SpringsColoradoActif, sans recrutement
Site 239ConroeTexasEn recrutement
Site 229Creve CouerMissouriRetiré
Site 102DallasTexasActif, sans recrutement
Site 343DenverColoradoEn recrutement
Site 349EvergreenColoradoActif, sans recrutement
Site 345EvergreenColoradoActif, sans recrutement
Site 277FairfaxVirginiaEn recrutement
Site 238FayettevilleGeorgiaEn recrutement
Site 148Fort WorthTexasRetiré
Site 347Fort WorthTexasArrêté prématurément
Site 217GlendaleCaliforniaActif, sans recrutement
Site 279HattiesburgMississippiRetiré
Site 199HickoryNorth CarolinaActif, sans recrutement
Site 320HoustonTexasEn recrutement
Site 275HoustonTexasEn recrutement
Site 215JacksonMississippiActif, sans recrutement
Site 335LafayetteCaliforniaEn recrutement
Site 335LafayetteCaliforniaEn recrutement
Site 344Las VegasNevadaEn recrutement
Site 209Los AngelesCaliforniaActif, sans recrutement
Site 240MankatoMinnesotaEn recrutement
Site 201MarreroLouisianaArrêté prématurément
Site 219MatherCaliforniaEn recrutement
Site 350MediaPennsylvaniaRetiré
Site 225Miami GardensFloridaActif, sans recrutement
Site 190Miami LakesFloridaActif, sans recrutement
Site 265MinneapolisMinnesotaEn recrutement
Site 194Mission ViejoCaliforniaArrêté prématurément
Site 206Missouri CityTexasRetiré
Site 198MonroeLouisianaArrêté prématurément
Site 267MoorparkCaliforniaEn recrutement
Site 352MoosicPennsylvaniaActif, sans recrutement
Site 283New YorkNew YorkEn recrutement
Site 319New YorkNew YorkActif, sans recrutement
Site 214NorwalkConnecticutRetiré
Site 161OkeechobeeFloridaActif, sans recrutement
Site 195Oklahoma CityOklahomaArrêté prématurément

25 sites supplémentaires sont indiqués dans la fiche du registre.

Documents de l'étude

Aucun document n'est lié dans cette fiche du registre.

Évolution au fil du temps

  1. 26 octobre 2026

    Objectif de recrutement modifié

    Enrollment target revised up from 321 to 325

    321325

  2. 26 octobre 2026

    Site ajouté

    30 sites added (75 total)

    4575